The UK Health Security Agency (UKHSA) has issued a warning after 38 cases of botulism poisoning in England were linked to unlicensed Botox-like injections. The cases were reported between 4 June and 14 July 2025, initially in the north-east, with further cases in the east of England and East Midlands.
Investigations suggest the use of an unlicensed Botox-like product. Symptoms of botulism include difficulty swallowing, slurred speech, and breathing difficulties requiring respiratory support. Botulism, caused by toxins from Clostridium botulinum bacteria, can be life-threatening and requires treatment with anti-toxins and supportive care.
Dr Gauri Godbole, consultant medical microbiologist at UKHSA, warned that symptoms can take up to four weeks to develop after treatment. She advised anyone experiencing symptoms to contact NHS 111. The UKHSA urged the public to ensure practitioners use licensed products and are appropriately qualified.
Prof Meghana Pandit, co-national medical director at NHS England, stressed that only registered professionals such as doctors, nurses, or pharmacy prescribers should administer these treatments. Dr Alison Cave, chief safety officer at the MHRA, warned that unlicensed products pose significant risks as they do not meet UK quality and safety standards.
